

## Daftar Pustaka

- Abdelbadie A, Mustafa R, Omer H, Abdalla S, Mohamed S. 2010. HER2 Over Expression in Malignant Palpable Breast Lumps of Pre and Postmenopausal Women Attending RICK. *Sudan JMS*. 5(4):255–259.
- Abdelzاهر E, El-Gendi SM, Yehya A, Gowil AG. 2011. Recurrence of benign meningiomas: Predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression. *Br. J. Neurosurg*. 25(6):707–713.
- Abtahi S, Hakimrabet S, Malekzadeh M, Deghanian AR, Ghaderi A. 2018. Investigating the levels of soluble extracellular domain of HER2 protein in the sera of meningioma patients. *Turk. Neurosurg*. 29(1):9–13.
- Andersson U, Guo D, Malmer B, Bergenheim AT, Brännström T, Hedman H, Henriksson R. 2004. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. *Acta Neuropathol*. 108(2):135–142.
- Ariafar A, Hasheminejad MS, Abtahi S, Ghaderi A. 2019. Investigating the levels of shed extracellular domain of HER2 protein in the sera of bladder cancer patients. *Middle East J. Cancer*. 10(1):30–36.
- Arnli MB, Winther TL, Lydersen S, Torp SH. 2018. Prognostic value of ErbB2/HER2 in human meningiomas. *PLoS One*. 13(10):1–12.
- Banan R, Hartmann C. 2017. The new WHO 2016 classification of brain tumors—what neurosurgeons need to know. *Acta Neurochir. (Wien)*. 159(3):403–418.
- Carlberg M, Söderqvist F, Hansson Mild K, Hardell L. 2013. Meningioma patients diagnosed 2007-2009 and the association with use of mobile and cordless phones: A case-control study. *Environ. Heal. A Glob. Access Sci. Source*. 12(1):1–10.
- Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. 2003. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. *Clin. Chem*. 49(10):1579–1598.
- Carvalho GTC de, Silva-Martins WC da, Magalhães KCSF de, Nunes CB, Soares AN, Tafuri LS de A, Simões RT. 2020. Recurrence/Regrowth in Grade I Meningioma: How to Predict? *Front. Oncol*. 10(1):1–15.
- Choy WC, Kim W, Nagasawa D, Stramotas S, Yew D, Gopen Q, Parsa AT, Yang IC. 2011. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. *Neurosurg. Focus*. 30(5):1–12.
- Czogalla B, Kahaly M, Mayr D, Schmoeckel E, Niesler B, Hester A, Zeder-Göb C, Kolben T, Burges A, Mahner S, et al. 2019. Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology. *Cancer Manag. Res*. 11:7673–7684.
- Dittadi R, Zancan M, Perasole A, Gion M. 2001. Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay. *Int. J. Biol. Markers*. 16(4):255–261.

- Domingues P, González-Tablas M, Otero Á, Pascual D, Ruiz L, Miranda D, Sousa P, Gonçalves JM, Lopes MC, Orfao A, *et al.* 2015. Genetic/molecular alterations of meningiomas and the signaling pathways targeted. *Oncotarget*. 6(13):10671–10688.
- Fakhrjou A, Meshkini A, Sadhrvan S. 2012. Status of Ki-67, estrogen and progesterone receptors in various subtypes of intracranial meningiomas. *Pakistan J. Biol. Sci.* 15(11):530–535.
- Ferreira PMP, Pessoa C. 2017. Molecular biology of human epidermal receptors, signaling pathways and targeted therapy against cancers: New evidences and old challenges. *Brazilian J. Pharm. Sci.* 53(2):1–17.
- Fogh SE, Johnson DR, Barker FG, Brastianos PK, Clarke JL, Kaufmann TJ, Oberndorfer S, Preusser M, Raghunathan A, Santagata S, *et al.* 2016. Case-based review: Meningiomas. *Neuro-Oncology Pract.* 3(2):120–134.
- Gammon MD, Hibshoosh H, Terry MB, Bose S, Schoenberg JB, Brinton LA, Bernstein JL, Thompson WD. 1999. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. *Cancer Epidemiol. Biomarkers Prev.* 8(5):413–419.
- Grondahl TB, Moen BH, Arnli MB, Torseth K, Torp SH. 2014. Immunohistochemical characterization of brain-invasive meningiomas. *Int. J. Clin. Exp. Pathol.* 7(10):7206–7219.
- Grondahl TB, Moen BH, Torp SH. 2012. The histopathological spectrum of human meningiomas. *Int. J. Clin. Exp. Pathol.* 5(3):231–242.
- Gurcay A, Bozkurt I, Senturk S, Kazanci A, Gurcan O, Turkoglu O, Beskonakli E. 2018. Diagnosis, treatment, and management strategy of meningioma during pregnancy. *Asian J. Neurosurg.* 13(1):86–89.
- Harland TA, Freeman JL, Davern M, McCracken DJ, Celano EC, Lillehei K, Olson JJ, Ormond DR. 2018. Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma. *J. Neurooncol.* 136(2):327–333.
- Houshmandi SS, Emnett RJ, Giovannini M, Gutmann DH. 2009. The Neurofibromatosis 2 Protein, Merlin, Regulates Glial Cell Growth in an ErbB2- and Src-Dependent Manner. *Mol. Cell. Biol.* 29(6):1472–1486.
- Hunt P, DeMonte F, Tang R, Su S, Raza S. 2017. Surgical Resection of an Optic Nerve Sheath Meningioma: Relevance of Endoscopic Endonasal Approaches to the Optic Canal. *J. Neurol. Surg. Reports.* 78(2):81–85.
- Ibebuike K, Ouma J. 2014. Demographic profile of patients diagnosed with intracranial Meningiomas in two academic hospitals in Johannesburg, South Africa: A 12-month prospective study. *Afr. Health Sci.* 14(4):939–945.
- Iqbal B, Buch A. 2016. Hormone receptor (ER, PR, HER2/neu) status and proliferation index marker (Ki-67) in breast cancers: Their onco-pathological correlation, shortcomings and future trends. *Med. J. Dr. D.Y. Patil Univ.* 9(6):674–679.
- Iqbal N, Iqbal N. 2014. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. *Mol. Biol. Int.* (852748):1–9.
- Jacobsen BM, Horwitz KB. 2012. Progesterone receptors, their isoforms and

- progesterone regulated transcription. *Mol. Cell. Endocrinol.* 357(1):18–29.
- Jeong J, Kim W, Kim LK, Van Houten J, Wysolmerski JJ. 2017. HER2 signaling regulates HER2 localization and membrane retention. *PLoS One.* 12(4):1–16.
- Kandemir NO, Ege Gül A, Doğan Gün B, Karadayi N, Yurdakan G, Özdamar ŞO. 2010. Her-2/Neu, Estrogen and Progesterone Receptor Expression In WHO Grade I Meningiomas. *Trak. Univ. Tip Fak. Derg.* 27(3):292–296.
- Kaul D, Budach V, Graaf L, Gollrad J, Badakhshi H. 2015. Outcome of Elderly Patients with Meningioma after Image-Guided Stereotactic Radiotherapy: A Study of 100 Cases. *Biomed Res. Int.* 2015(868401):1–6.
- Kerr K, Qualmann K, Esquenazi Y, Hagan J, Kim DH. 2018. Familial syndromes involving meningiomas provide mechanistic insight into sporadic disease. *Clin. Neurosurg.* 83(6):1107–1118.
- Khamis NN, Rashwan MF. 2011. Prognostic role of Her2/neu, progesterone receptor, and MIB-1 expression in meningioma. *Egypt. J. Pathol.* 31(2):104–112.
- Kong SY, Nam BH, Lee KS, Kwon Y, Lee ES, Seong MW, Lee DH, Ro J. 2006. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. *Clin. Chem.* 52(8):1510–1515.
- Krishnamurti U, Silverman JF. 2014. HER2 in breast cancer: A review and update. *Adv. Anat. Pathol.* 21(2):100–107.
- Lamb CA, Fabris VT, Jacobsen BM, Molinolo A, Lanari C. 2018. Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer. *Endocr. Relat. Cancer.* 25(12):R605–R624.
- Leary AF, Hanna WM, Van De Vijver MJ, Penault-Llorca F, Rüschoff J, Osamura RY, Bilous M, Dowsett M. 2009. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. *J. Clin. Oncol.* 27(10):1694–1705.
- Lee E, Grutsch J, Persky V, Glick R, Mendes J, Davis F. 2006. Association of meningioma with reproductive factors. *Int. J. Cancer.* 119(5):1152–1157.
- Lee S, Karas PJ, Hadley CC, Bayley V. JC, Basit Khan A, Jalali A, Sweeney AD, Klisch TJ, Patel AJ. 2019. The role of merlin/NF2 loss in meningioma biology. *Cancers (Basel).* 11(11):1–14.
- Lee SH, Lee YS, Hong YG, Kang CS. 2014. Significance of COX-2 and VEGF expression in histopathologic grading and invasiveness of meningiomas. *APMIS.* 122(1):16–24.
- Leng L. 2016. The relationship between mobile phone use and risk of brain tumor: A systematic review and meta-analysis of trails in the last decade. *Chinese Neurosurg. J.* 2(38):1–10.
- Liu PCC, Liu X, Li Y, Covington M, Wynn R, Huber R, Hillman M, Yang G, Ellis D, Marando C, *et al.* 2006. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. *Cancer Biol. Ther.* 5(6):657–664.
- Lorona NC, Cook LS, Tang MTC, Hill DA, Wiggins CL, Li CI. 2019. Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer. *Horm. Cancer.* 10(2-3):71–76.

- Loussouarn D, Brunon J, Avet-Loiseau H, Campone M, Mosnier JF. 2006. Prognostic value of HER2 expression in meningiomas: An immunohistochemical and fluorescence in situ hybridization study. *Hum. Pathol.* 37(4):415–421.
- Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, Pacifico E, Tofanetti FR, Sidoni A, Basurto C, *et al.* 2008. Evaluation of serum HER2 extracellular domain in early breast cancer patients: Correlation with clinicopathological parameters and survival. *Ann. Oncol.* 19(5):883–890.
- Ma L, Yang HY, Han XH, Li J, Wang F, Zhang CL, Yao JR, Shi YK. 2012. Relationship between serum HER2 extra cellular domain levels, tissue HER2 expression, and clinico-pathological parameters in early stage breast cancer. *Chin. Med. J. (Engl.)*. 125(22):4104–4110.
- Mahzouni P, Movahedipour M. 2012. An immunohistochemical study of HER2 expression in meningioma and its correlation with tumor grade. *Pathol. Res. Pract.* 208(4):221–224.
- Michie KA, Bermeister A, Robertson NO, Goodchild SC, Curmi PMG. 2019. Two Sides of the Coin: Ezrin/Radixin/Moesin and Merlin Control Membrane Structure and Contact Inhibition. *Int. J. Mol. Sci.* 20(8):1–40.
- Milano MT, Grossman CE. 2014. Meningioma in breast cancer patients: population-based analysis of clinicopathologic characteristics. *Am. J. Clin. Oncol. Cancer Clin. Trials.* 40(1):11–16.
- Morath I, Jung C, Lévêque R, Linfeng C, Toillon RA, Warth A, Orian-Rousseau V. 2018. Differential recruitment of CD44 isoforms by ERBB ligands reveals an involvement of CD44 in breast cancer. *Oncogene.* 37(11):1472–1484.
- Nigim F, Wakimoto H, Kasper EM, Ackermans L, Temel Y. 2018. Emerging medical treatments for meningioma in the molecular era. *Biomedicines.* 6(3):1–21.
- Ongaratti BR, Silva CBO, Trott G, Haag T, Leães CGS, Ferreira NP, Oliveira MC, Pereira-Lima JFS. 2016. Expression of Merlin, NDRG2, ERBB2, and c-MYC in meningiomas: Relationship with tumor grade and recurrence. *Brazilian J. Med. Biol. Res.* 49(4):4–9.
- Parker RT, Ovens CA, Fraser CL, Samarawickrama C. 2018. Optic nerve sheath meningiomas: Prevalence, impact, and management strategies. *Eye Brain.* 10:85–99.
- Plum PS, Gebauer F, Krämer M, Alakus H, Berlth F, Chon S-H, Schiffmann L, Zander T, Büttner R, Hölscher AH, *et al.* 2019. Her2 Expression and Gene Amplification Correlates With Better Survival in Esophageal Adenocarcinoma. *BMC Cancer.* 19(38):1–9.
- Radisky ES, Radisky DC. 2015. Matrix metalloproteinases as breast cancer drivers and therapeutic targets. *Front. Biosci. - Landmark.* 20(7):1144–1163.
- Rashed M Al, Foshay K, Abedalthagafi M. 2020. Recent Advances in Meningioma Immunogenetics. *Front. Oncol.* 9:1–11.
- Reszec J, Hermanowicz A, Rutkowski R, Turek G, Mariak Z, Chyczewski L. 2015. Expression of MMP-9 and VEGF in meningiomas and their

- correlation with peritumoral brain edema. *Biomed Res. Int.* (646853):1–8.
- Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, Schiff D, Weber DC, Wen PY, Vogelbaum MA. 2015. Meningiomas: Knowledge base, treatment outcomes, and uncertainties. A RANO review. *J. Neurosurg.* 122(1):4–23.
- Ryu H-S, Moon K-S, Lee K-H, Jang W-Y, Jung T-Y, Kim I-Y, Jung S. 2017. Recurred Intracranial Meningioma: A Retrospective Analysis for Treatment Outcome and Prognostic Factor. *Brain Tumor Res. Treat.* 5(2):54.
- Saito M, Kato Y, Ito E, Fujimoto J, Ishikawa K, Doi A, Kumazawa K, Matsui A, Takebe S, Ishida T, *et al.* 2012. Expression screening of 17q12-21 amplicon reveals GRB7 as an ERBB2-dependent oncogene. *FEBS Lett.* 586(12):1708–1714.
- Sandberg D, Tolmachev V, Velikyan I, Olofsson H, Wennborg A, Feldwisch J, Carlsson J, Lindman H, Sörensen J. 2017. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. *Eur. J. Nucl. Med. Mol. Imaging.* 44(8):1337–1346.
- Saraf S, McCarthy BJ, Villano JL. 2011. Update on Meningiomas. *Oncologist.* 16:1604–1613.
- Sastroasmoro S, Ismail S. 2011. *Dasar-dasar Metodologi Penelitian Klinis.* Jakarta: Sagung Seto.
- Sauter G, Lee J, Bartlett JMS, Slamon DJ, Press MF. 2009. Guidelines for human epidermal growth factor receptor 2 testing: Biologic and methodologic considerations. *J. Clin. Oncol.* 27(8):1323–1333.
- Sety LM. 2014. Jenis Pemakaian Kontrasepsi Hormonal dan Gangguan Menstruasi. *J. Kesehat.* V(1):60–66.
- Shaikh N, Dixit K, Raizer J. 2018. Recent advances in managing/understanding meningioma [version 1; referees: 2 approved]. *F1000Research.* 7(490):1–8.
- Shi HZ, Wang YN, Huang XH, Zhang KC, Xi HQ, Cui JX, Liu GX, Liang WT, Wei B, Chen L. 2017. Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer. *World J. Gastroenterol.* 23(10):1836–1842.
- Shivapathasundram G, Wickremesekera AC, Tan ST, Itinteang T. 2017. Tumour stem cells in meningioma: A review. *J. Clin. Neurosci.* 47:66–71.
- Shukla S, Singh BK, Pathania OP, Jain M. 2016. Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer. *Indian J. Med. Res. Suppl.* 143(May):52–58.
- Šlaus NP. 2013. Merlin, the NF2 gene product. *Pathol. Oncol. Res.* 19(3):365–373.
- Soriano LC, Wallander MA, Garca Rodriguez LA. 2012. Epidemiology of meningioma in the United Kingdom. *Neuroepidemiology.* 39(1):27–34.
- Supartoto A, Sasongko MB, Respatika D, Mahayana IT, Pawiroranu S, Kusnanto H, Sakti DH, Nurlaila PS, Heriyanto DS, Haryana SM. 2019. Relationships between neurofibromatosis-2, progesterone receptor expression, the use of exogenous progesterone, and risk of orbitocranial meningioma in females. *Front. Oncol.* 8(651):1–7.

- Tandean S, Indharty RS, Japardi I, Ilmu D, Saraf B, Kedokteran F, Sumatera U, Rsup U, Malik HA. 2013. Hubungan antara reseptor progesteron dengan Ki-67 labeling index pada meningioma. *Maj. Kedokt. Nusant.* 46(1):17–20.
- Waage IS, Vreim I, Torp SH. 2013. C-erbB2/HER2 in human gliomas, medulloblastomas, and meningiomas: A minireview. *Int. J. Surg. Pathol.* 21(6):573–582.
- Wernicke AG, Dicker AP, Whiton M, Ivanidze J, Hyslop T, Hammond EH, Perry A, Andrews DW, Kenyon L. 2010. Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. *Radiat. Oncol.* 5(1):1–7.
- Wickremesekera A, Hovens CM, Kaye AH. 2010. Expression of ErbB-1 and ErbB-2 in meningioma. *J. Clin. Neurosci.* 17(9):1155–1158.
- Wiemels J, Wrensch M, Claus EB. 2010. Epidemiology and etiology of meningioma. *J. Neurooncol.* 99(3):307–314.
- Wigertz A, Lönn S, Hall P, Auvinen A, Christensen HC, Johansen C, Klæboe L, Salminen T, Schoemaker MJ, Swerdlow AJ, *et al.* 2008. Reproductive factors and risk of meningioma and glioma. *Cancer Epidemiol. Biomarkers Prev.* 17(10):2663–2670.
- Wohrer A. 2013. Epidemiology of Meningioma. *Eur. Assoc. NeuroOncology Mag.* 3(3):95–96.
- Yang CC, Tsai CC, Chen SJ, Chiang MF, Lin JF, Hu CK, Chan Y kai, Lin HY, Cheng SY. 2018. Factors Associated with Recurrence of Intracranial Meningiomas After Surgical Resection: A Retrospective Single-Center Study. *Int. J. Gerontol.* 12(1):57–61.
- Zettira Z, Nisa K. 2015. Analisis Hubungan Penggunaan Kontrasepsi Hormonal dengan Disfungsi Seksual pada Wanita. *Majority.* 4(7):103–108.